MedTrace Logo

A Randomized, Controlled Trial to Evaluate CT Image Quality Lumentin® 44

NCT03326518 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-10-27

Study results available
· View outcomes & findings →

Summary

Subjects referred for abdominal or thoracoabdominal CT-examination will be randomised to either the three contrast agents Lumentin® 44, Omnipaque® or Movprep. The difference in contrast density, as observed in the CT-examination, between lumen and wall (mucosal lining) will be compared by the three contrast agents.

Conditions

  • Subjects Referred to CT-examination of the Abdomen

Interventions

DIAGNOSTIC_TEST

Lumentin® 44

Contrast agent

DIAGNOSTIC_TEST

Diluted Omnipaque®

Contrast agent

DIAGNOSTIC_TEST

Movprep®

Contrast agent

Sponsors & Collaborators

  • Lument AB

    lead INDUSTRY

Principal Investigators

  • Peter Leander, Ass. Prof. · Skanes University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-28
Primary Completion
2018-09-30
Completion
2019-02-15

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03326518 on ClinicalTrials.gov